Citadel Advisors
LUNG icon

Citadel Advisors’s Pulmonx LUNG Stock Holding History

Citadel Advisors’s Portfolio LUNG Stock Details LUNG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74.9K Buy
+57,600
New +$79.3K ﹤0.01% 12885
2025
Q2 		– Sell
-2,600
Closed -$17.5K – 13989
2025
Q1 		$17.5K Buy
2,600
+2,100
+420% +$14.9K ﹤0.01% 13238
2024
Q4 		$3.4K Buy
500
+200
+67% +$1.32K ﹤0.01% 13998
2024
Q3 		$2.49K Sell
300
-100
-25% -$724 ﹤0.01% 13744
2024
Q2 		$2.54K Sell
400
-800
-67% -$6.15K ﹤0.01% 13674
2024
Q1 		$11.1K Sell
1,200
-12,000
-91% -$141K ﹤0.01% 13428
2023
Q4 		$168K Sell
13,200
-3,300
-20% -$34.4K ﹤0.01% 10215
2023
Q3 		$170K Sell
16,500
-7,100
-30% -$82.2K ﹤0.01% 10159
2023
Q2 		$309K Sell
23,600
-19,000
-45% -$232K ﹤0.01% 8982
2023
Q1 		$476K Buy
42,600
+41,200
+2,943% +$407K ﹤0.01% 8422
2022
Q4 		$11.8K Buy
+1,400
New +$13.3K ﹤0.01% 13552
2022
Q1 		– Sell
-12,800
Closed -$411K – 14174
2021
Q4 		$411K Sell
12,800
-2,400
-16% -$87.7K ﹤0.01% 10148
2021
Q3 		$547K Buy
+15,200
New +$598K ﹤0.01% 9641
2021
Q2 		– Sell
-18,100
Closed -$828K – 14086
2021
Q1 		$828K Buy
+18,100
New +$1.04M ﹤0.01% 8567

Other funds holding LUNG

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ECM
ExodusPoint Capital Management New York $15.5B AUM 38.81% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Citadel Advisors's LUNG Position: Q2 2026 in Review

Citadel Advisors increased its Pulmonx (LUNG) stake by 152% in Q2 2026, buying an estimated $119K and bringing the position to 143,404 shares worth $186K. The position accounts for ﹤0.01% of the portfolio, ranked #12144.

Citadel Advisors first reported a position in LUNG in Q4 2020 and has held it in 23 quarters since. The position peaked at $16M in Q3 2021. 107 funds tracked by Wall St. Rank hold LUNG as of Q2 2026.

  • Citadel Advisors held 143,404 shares of Pulmonx worth $186K as of Q2 2026.
  • Citadel Advisors bought 86,395 Pulmonx shares in Q2 2026, an estimated $119K.
  • Pulmonx made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12144 holding.
  • Citadel Advisors first reported a position in Pulmonx in Q4 2020 and has held it in 23 quarters since.
  • Citadel Advisors's Pulmonx position peaked at $16M in Q3 2021.
  • 107 funds tracked by Wall St. Rank held Pulmonx as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.